Mackenzie Financial’s Altimmune ALT Stock Holding History

Mackenzie Financial’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-50	Closed	-$49K	–	638
2016 Q4	$49K	Buy	+50	New	+$44.8K	﹤0.01%	637

Other funds holding ALT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Mackenzie Financial's ALT Position: Q1 2017 in Review

Mackenzie Financial sold out of Altimmune (ALT) in Q1 2017, closing a stake of 50 shares — an estimated $49K sold.

Mackenzie Financial first reported a position in ALT in Q4 2016 and held it in 1 quarter. The position peaked at $49K in Q4 2016. 71 funds tracked by Wall St. Rank hold ALT as of Q1 2017.

Mackenzie Financial reported no remaining Altimmune position as of Q1 2017 after selling out during the quarter.
Mackenzie Financial sold 50 Altimmune shares in Q1 2017, an estimated $49K.
Mackenzie Financial first reported a position in Altimmune in Q4 2016 and held it in 1 quarter.
Mackenzie Financial's Altimmune position peaked at $49K in Q4 2016.
71 funds tracked by Wall St. Rank held Altimmune as of Q1 2017.

Based on Mackenzie Financial's 13F filing for Q1 2017, filed 12 May 2017.